Gain Therapeutics

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies, today announces the appointment of Jonas Hannestad, M.D., Ph.D. as its chief medical officer, effective as of March 25, 2024.

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the year ended December 31, 2023 and provides a corporate update.

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr. Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr.

Gain Therapeutics to Present at Public Ventures Discovery Day

Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces the initiation of the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial of GT-02287, Gain's lead drug candidate for the treatment of GBA1 Parkinson's disease.

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST

Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm

UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

Gain Therapeutics, Inc. (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know

Gain Therapeutics' drug candidate GT-02287 targets GCase and lysosomal dysfunction, potentially succeeding where others may fail. The company's AI-driven drug discovery engine has generated several targets across different diseases. GT-02287 is currently in a Phase 1 trial for GBA-1-PD, and Gain will add further preclinical data in February to its already interesting preclinical dataset.

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Presentation will highlight new data of GT-02287 in preclinical models of Parkinson's disease Presentation will highlight new data of GT-02287 in preclinical models of Parkinson's disease

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

The biotech bear market has presented investment opportunities for investors to take meaningful stakes of public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success using its physics-based approach to finding allosteric binding sites on proteins. Recent investment activity and biopharma deals have reduced financial risks for Gain Therapeutics and provided additional valuation comparisons.

Doubling Down On Gain Therapeutics

After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics, Inc. (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now

Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will participate on a panel during the AI Driven Drug Discovery Summit taking place at the Sheraton Boston Hotel, in Boston, Massachusetts December 5-6, 2023.

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an underwritten public offering of 2,545,000 shares of its common stock and warrants to purchase up to an aggregate of 1,272,500 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant, including 331,956 shares of common stock and warrants to purchase 165,978 shares of common stock issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $4.01 per set of securities, yielding an effective price of $2.00 per share and $0.01 per warrant. The warrants were sold at the rate of one warrant for every two shares of common stock. The warrants have an exercise price of $2.75 per share, are exercisable immediately, and will expire five years following the date of issuance.

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of 1,106,522 shares of its common stock at a combined public offering price of $2.005 per share and accompanying warrant. The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock is $4.01 per set of securities, yielding an effective price of $2.00 per share and $0.01 per warrant. The warrants are being sold at the rate of one warrant for every two shares of common stock. The warrants will have an exercise price of $2.75 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a press release from Gain Therapeutics, the company has started dosing the first two subjects in its Phase 1 clinical trial.

Why Is Gain Therapeutics (GANX) Stock Moving Today?

First small molecule allosteric binder discovered with Gain's computational drug discovery platform enters clinical development First small molecule allosteric binder discovered with Gain's computational drug discovery platform enters clinical development

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking place in New York, NY, September 26-28, 2023.

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer of Gain Therapeutics, will deliver a featured presentation at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference: Drug Discovery for Progressive Central Nervous System Disorders. The event is taking place at the Sheraton Boston in Boston, Massachusetts, between September 26-27, 2023.

Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference

First drug candidate identified with Gain's proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.

News for Gain Therapeutics Stock (GANX)